PharVision Advisers’s Toro Company TTC Stock Holding History

PharVision Advisers’s Portfolio TTC Stock Details TTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,300	Closed	-$338K	–	607
2025 Q4	$338K	Buy	+4,300	New	+$318K	0.17%	213

Other funds holding TTC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $10.9B AUM 27.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PharVision Advisers's TTC Position: Q1 2026 in Review

PharVision Advisers sold out of Toro Company (TTC) in Q1 2026, closing a stake of 4,300 shares — an estimated $338K sold.

PharVision Advisers first reported a position in TTC in Q4 2025 and held it in 1 quarter. The position peaked at $338K in Q4 2025. 580 funds tracked by Wall St. Rank hold TTC as of Q1 2026.

PharVision Advisers reported no remaining Toro Company position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 4,300 Toro Company shares in Q1 2026, an estimated $338K.
PharVision Advisers first reported a position in Toro Company in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Toro Company position peaked at $338K in Q4 2025.
580 funds tracked by Wall St. Rank held Toro Company as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.